Barclays Maintains Equal-Weight on Ionis Pharmaceuticals, Raises Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Equal-Weight rating on Ionis Pharmaceuticals (NASDAQ:IONS) and raises the price target from $45 to $51.
August 02, 2024 | 3:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Gena Wang maintains an Equal-Weight rating on Ionis Pharmaceuticals and raises the price target from $45 to $51.
The raised price target from $45 to $51 by Barclays suggests a positive outlook for Ionis Pharmaceuticals, which could lead to a short-term increase in stock price. However, the Equal-Weight rating indicates a neutral stance, balancing the impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100